Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML-Reference-Cited by-同舟云学术

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Published:2016-03-21 Issue:39 Volume:35 Page:5119-5131
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Lindblad O,Cordero E,Puissant A,Macaulay L,Ramos A,Kabir N N,Sun J,Vallon-Christersson J,Haraldsson K,Hemann M T,Borg Å,Levander F,Stegmaier K,Pietras K,Rönnstrand L,Kazi J U

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc201641.pdf

Reference46 articles.

1. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187.

2. Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.

3. Masson K, Rönnstrand L . Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 2009; 21: 1717–1726.

4. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624–631.

5. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380.

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy;Critical Reviews in Oncology/Hematology;2024-09

2. Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia;Annals of Hematology;2024-08-29

3. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors;Journal of Medicinal Chemistry;2024-04-24

4. Paclitaxel mediates the PI3K/AKT/mTOR pathway to reduce proliferation of FLT3‑ITD⁺ AML cells and promote apoptosis;Experimental and Therapeutic Medicine;2024-02-23

5. Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD;Cancers;2023-11-15